590 related articles for article (PubMed ID: 23830844)
1. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
[TBL] [Abstract][Full Text] [Related]
2. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients.
Hecking M; Kainz A; Bielesz B; Plischke M; Beilhack G; Hörl WH; Sunder-Plassmann G; Bieglmayer C
Clin Biochem; 2012 Dec; 45(18):1645-51. PubMed ID: 23217247
[TBL] [Abstract][Full Text] [Related]
4. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
[TBL] [Abstract][Full Text] [Related]
5. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
[TBL] [Abstract][Full Text] [Related]
6. Mineral-bone metabolism markers in young hemodialysis patients.
Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
[TBL] [Abstract][Full Text] [Related]
7. Influence of PTH assay methodology on differential diagnosis of renal bone disease.
Reichel H; Esser A; Roth HJ; Schmidt-Gayk H
Nephrol Dial Transplant; 2003 Apr; 18(4):759-68. PubMed ID: 12637646
[TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
9. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
Janckila AJ; Lederer ED; Price BA; Yam LT
Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
[TBL] [Abstract][Full Text] [Related]
10. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
Fujimori A; Okada S; Sakai M; Tome K; Fukagawa M
Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
[TBL] [Abstract][Full Text] [Related]
11. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD).
Manghat P; Souleimanova I; Cheung J; Wierzbicki AS; Harrington DJ; Shearer MJ; Chowienczyk P; Fogelman I; Nerlander M; Goldsmith D; Hampson G
Bone; 2011 May; 48(5):1127-32. PubMed ID: 21281749
[TBL] [Abstract][Full Text] [Related]
12. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
13. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
[TBL] [Abstract][Full Text] [Related]
14. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
Nowak Z; Konieczna M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
[TBL] [Abstract][Full Text] [Related]
15. Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
Kihara T; Ichikawa H; Morimoto H; Yano A; Akagi S; Nakao K; Kohmoto H; Wada J; Kumagai I; Makino H
Nephron Clin Pract; 2004; 98(3):c93-100. PubMed ID: 15528944
[TBL] [Abstract][Full Text] [Related]
16. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
[TBL] [Abstract][Full Text] [Related]
17. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
18. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
20. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
